About: Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact
Creator	Barr, Ian Middleton, Deborah Hurt, Aeron Kelso, Anne Arkinstall, Rachel Haining, Jessica Mccaw, James Mcvernon, Jodie Sullivan, Sheena Oh, Ding Lowther, Sue Leang, Sook-Kwan
Source	PMC
abstract	OBJECTIVES: The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled NAIs and developed pandemic plans for the use of antiviral drugs, based on either treatment of high-risk individuals and/or prophylaxis of contacts. However, to date there has been a lack of in vivo models to test the efficacy of treatment or prophylaxis with NAIs, for influenza-infected individuals or exposed contacts, in a household setting. METHODS: A ferret model of household contact was developed to study the efficacy of different prophylaxis regimens in preventing infection in contact ferrets exposed to influenza A(H1N1)pdm09-infected index ferrets. RESULTS: Among the different prophylactic regimens, contact ferrets receiving oseltamivir prophylaxis twice daily showed better outcomes than those receiving oseltamivir once daily. Benefits included a significant delay in the time to secondary infection, lower weight loss and higher activity levels. The treatment of index ferrets at 36 h post-infection did not influence either secondary infection rates or clinical symptoms in exposed contact ferrets. Neither prophylaxis nor treatment prevented infection or reduced the duration of viral shedding, although clinical symptoms did improve in infected animals receiving prophylaxis. CONCLUSIONS: Different oseltamivir prophylaxis regimens did not prevent infections, but consistently resulted in a reduction in symptoms in infected ferrets. However, oseltamivir prophylaxis failed to reduce viral titres, which warrants further investigation in humans.
has issue date	2014-05-19(xsd:dateTime)
bibo:doi	10.1093/jac/dku146
bibo:pmid	24840623
has license	cc-by-nc
sha1sum (hex)	5c9373411bb9e5bbfc3fd8f8cedc7635d9a9088f
schema:url	https://doi.org/10.1093/jac/dku146
resource representing a document's title	Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact
has PubMed Central identifier	PMC4130381
has PubMed identifier	24840623
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:5c9373411bb9e5bbfc3fd8f8cedc7635d9a9088f#body_text
is schema:about of	named entity 'pandemic' named entity 'contacts' named entity 'models' named entity 'mitigate' named entity 'vivo' named entity 'H1N1' named entity 'oseltamivir' named entity 'prophylaxis' named entity 'infection' named entity 'clinical study' named entity 'equivalent dose' named entity 'oseltamivir' named entity 'CSIRO' named entity 'viral load' named entity 'co-housing' named entity 'oseltamivir' named entity 'RT-PCR' named entity 'zanamivir' named entity 'shedding virus' named entity 'prophylaxis' named entity 'oseltamivir' named entity 'antibody response' named entity 'AAHL' named entity 'pharmaceutical' named entity 'infection' named entity 'post-exposure prophylaxis' named entity 'proof-of-concept' named entity 'prophylactic' named entity 'post-exposure' named entity 'A(H1N1)pdm09' named entity 'pathogenesis' named entity 'clinical studies' named entity 'oseltamivir' named entity 'postexposure prophylaxis' named entity 'post-exposure' named entity 'antibody' named entity 'ferret' named entity 'prophylaxis' named entity 'statistically significant' named entity 'weight loss' named entity 'significant effect' named entity 'viruses' named entity 'ferret' named entity 'prophylaxis' named entity 'viruses' named entity 'viral infections' named entity 'prophylaxis' named entity 'ferret' named entity 'pre-exposure prophylaxis' named entity 'influenza virus' named entity 'clinical signs' named entity 'prophylaxis' named entity 'infection' named entity 'prophylaxis' named entity 'infection' named entity 'randomized controlled trial' named entity 'ferret' named entity 'prophylaxis' named entity 'ferret' named entity 'viral shedding' named entity 'orally administered' named entity 'oseltamivir' named entity 'antivirals' named entity 'log-rank test' named entity 'humans infected' named entity 'pharmacodynamic' named entity 'virus' named entity 'clinical symptoms' named entity 'haemagglutination inhibition' named entity 'nasal lavage'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software